Gilead Sciences Inc. has announced a strategic partnership with the Global Fund to Fight AIDS, Tuberculosis and Malaria to accelerate access to lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, for HIV prevention in primarily low- and lower-middle-income countries. This agreement will enable Gilead to supply the medicine to up to two million people over three years at no profit, while awaiting the availability of licensed generic versions. The European Medicines Agency has validated Gilead's application for lenacapavir under the EU-M4all procedure, which could expedite regulatory reviews in resource-limited countries. Gilead is actively collaborating with global aid organizations to ensure timely distribution and is pursuing strategies to support access in middle-income countries not covered by this agreement.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。